<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690660</url>
  </required_header>
  <id_info>
    <org_study_id>2020-00736; me20Burkard</org_study_id>
    <nct_id>NCT04690660</nct_id>
  </id_info>
  <brief_title>Basel Postpartum Hypertension Cohort</brief_title>
  <acronym>Basel-PPHT</acronym>
  <official_title>Basel Postpartum Hypertension Cohort (Basel-PPHT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, prospective observational, single-center registry is to study short-,&#xD;
      intermediate-and long-term course of postpartum hypertension and predictors/risk factors&#xD;
      associated with long term cardiovascular and renal risk.&#xD;
&#xD;
      Current disease management strategies will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2020</start_date>
  <completion_date type="Anticipated">May 2030</completion_date>
  <primary_completion_date type="Anticipated">May 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of persistent hypertension defined by 24 hours BP measurement</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of persistent hypertension defined by 24 hours BP measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM)</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of persistent hypertension defined by office blood pressure measurement (OBPM, AOBPM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of microalbuminuria</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of microalbuminuria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of damage to the retina of the eyes (retinopathy)</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of damage to the retina of the eyes (retinopathy)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs of hypertensive heart disease</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Signs of hypertensive heart disease at transthoracic echocardiography determined by left ventricular hypertrophy (LVH)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dyslipidemia</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of dyslipidemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of prediabetes/diabetes</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Frequency of prediabetes/diabetes</description>
  </primary_outcome>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Postpartum Hypertension (PPHT)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection for parameters of organ damage (cardiac and renal blood markers)</intervention_name>
    <description>Blood results will be taken out of next routine venipuncture. Routinely collected standard parameters are a blood count, chemistry panel including renal parameters and electrolytes, lipid profile and a HbA1c as well as albumin/creatinine and protein/creatinine ratio in urine.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection for blood pressure (BP)</intervention_name>
    <description>Clinic blood pressure and 24hour BP Measurements</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home-based blood pressure management (substudy)</intervention_name>
    <description>Subjects participating in home-based blood pressure management via telemonitoring will receive a free HekaHealth application (App) for the structured assessment of HBPM.</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker Profiles (substudy)</intervention_name>
    <description>Substudy where possible cardiac, renal and pregnancy related biomarkers will be additionally analyzed. The following biomarkers will be analyzed: N terminal (NT)-proBNP, Troponin, elevated mid-regional pro-atrial natriuretic peptide (ANP), elevated mid-regional pro adrenomedullin (ADM), soluble fms-like tyrosine kinase (sFlt-1), and placenta growth factor (PlGF).</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection on patient reported outcomes</intervention_name>
    <description>Data collection on patient reported outcomes (Questionnaire EQ-5D, Questionnaire for App based monitoring )</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples for biomarker&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will take place at the Hypertension Clinic of the Medical Outpatient Department&#xD;
        at the University Hospital Basel and the Department of Obstetrics and Gynaecology at the&#xD;
        University Hospital Basel. Participants will be consecutively screened and recruited by the&#xD;
        treating physicians and the Hypertension Team of the Hypertension Clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all women with hypertensive disorders of pregnancy&#xD;
&#xD;
          -  postpartum hypertension (blood pressure measurements of systolic ≥140 and/or diastolic&#xD;
             ≥ 90mmHg or antihypertensive therapy within the first 14 days after delivery)&#xD;
&#xD;
          -  women with preexisting hypertension or&#xD;
&#xD;
          -  women on antihypertensive medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  delivery &gt; 14 days&#xD;
&#xD;
          -  lack of consent to participate in the study, language barriers or lack of general&#xD;
             understanding&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thilo Burkard, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Outpatient Department and Hypertension Clinic, University Hospital BaselUni</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thilo Burkard, Dr. med.</last_name>
    <phone>+41 61 328 7738</phone>
    <email>thilo.burkard@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thenral Socrates, Dr. med.</last_name>
    <phone>+41 61 328 6647</phone>
    <email>thenral.socrates@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Outpatient Department and Hypertension Clinic, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thilo Burkhard, Dr. med.</last_name>
      <phone>+41 61 328 7738</phone>
      <email>thilo.burkard@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Thenral Socrates, Dr. med.</last_name>
      <phone>+41 61 328 6647</phone>
      <email>thenral.socrates@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Thilo Burkard, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thenral Socrates, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mayr, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Hösli, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olav Lapaire, Prof. Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 27, 2020</last_update_submitted>
  <last_update_submitted_qc>December 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pregnancy Induced Hypertension (PIH)</keyword>
  <keyword>Home Blood Pressure Monitoring (HBPM)</keyword>
  <keyword>Office Blood Pressure Monitoring (OBPM)</keyword>
  <keyword>Automated Office Blood Pressure Measurement (AOBPM)</keyword>
  <keyword>Gestational Hypertension</keyword>
  <keyword>HekaHealth Self-Measured Blood Pressure (SMBP) App</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

